Clinical and pathological features of combined hepatocellular–cholangiocarcinoma compared with other liver cancers
Kazuki Wakizaka(Hokkaido University), Akinobu Taketomi(Hokkaido University), Hirofumi Kamachi(Hokkaido University), Naoki Okada(Tokai University), Yuki Fujii(Hokkaido University), Hideki Yokoo(Hokkaido University), Takanori Ohata(Hokkaido University), Shingo Shimada(Hokkaido University), Akihisa Nagatsu(Hokkaido University), Toshiya Kamiyama(Hokkaido University), Koichi Kato(Hokkaido University), Tatsuya Orimo(Hokkaido University), Ko Sugiyama(Hokkaido University), Masafumi Ohira(Hokkaido University)
Cited by 92
Related Papers
Interleukin‐6/<scp>STAT</scp>3 signaling as a promising target to improve the efficacy of cancer immunotherapy
|Cancer Science|2017|295
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272
Long‐term and perioperative outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with propensity score matching: a multi‐institutional Japanese study
|Journal of Hepato-Biliary-Pancreatic Sciences|2015|267
Randomized phase <scp>III</scp> study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (<scp>KHBO1401</scp>‐ <scp>MITSUBA</scp>)
|Journal of Hepato-Biliary-Pancreatic Sciences|2022|244